This bill amends Minnesota Statutes 2024, section 256B.0625, subdivision 13g, to require that nonopioid drugs approved by the United States Food and Drug Administration (FDA) for the treatment or management of pain are not disadvantaged in coverage compared to opioid or narcotic drugs on the preferred drug list. Specifically, the commissioner must ensure that nonopioid drugs are not designated as nonpreferred if any opioid or narcotic drug is preferred, and that the utilization management protocols for nonopioid drugs are not more restrictive than those for opioids. The bill also clarifies that this requirement applies immediately upon FDA approval of a nonopioid drug, regardless of its review status by the commissioner or the Formulary Committee.

Additionally, the bill includes several insertions that enhance the transparency and public engagement in the process of modifying the preferred drug list. It mandates that the commissioner consider the implications of any deletions or modifications on public health policies and health disparities, conduct public hearings prior to such changes, and provide adequate notice to the public. The bill also specifies that the preferred drug list must be published annually and maintained on the Department of Human Services website, ensuring that the public has access to current and historical information regarding the list.

Statutes affected:
Introduction: 256B.0625